Search Results - "Smilek, Dawn"

Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort by Dall'Era, Maria, Cisternas, Miriam G., Smilek, Dawn E., Straub, Laura, Houssiau, Frédéric A., Cervera, Ricard, Rovin, Brad H., Mackay, Meggan

“…Objective There is a need to determine which response measures in lupus nephritis trials are most predictive of good long‐term renal function. We used data…”
Get full text

A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis by McKinney, Eoin F., Cuthbertson, Iona, Harris, Kristina M., Smilek, Dawn E., Connor, Christopher, Manferrari, Giulia, Carr, Edward J., Zamvil, Scott S., Smith, Kenneth G. C.

“…Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) with the majority of cases characterised by…”
Get full text

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis by Atisha‐Fregoso, Yemil, Malkiel, Susan, Harris, Kristina M., Byron, Margie, Ding, Linna, Kanaparthi, Sai, Barry, William T., Gao, Wendy, Ryker, Kristin, Tosta, Patti, Askanase, Anca D., Boackle, Susan A., Chatham, W. Winn, Kamen, Diane L., Karp, David R., Kirou, Kyriakos A., Sam Lim, S., Marder, Bradley, McMahon, Maureen, Parikh, Samir V., Pendergraft, William F., Podoll, Amber S., Saxena, Amit, Wofsy, David, Diamond, Betty, Smilek, Dawn E., Aranow, Cynthia, Dall’Era, Maria

“…Objective To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis…”
Get full text

Restoring the balance: immunotherapeutic combinations for autoimmune disease by Smilek, Dawn E, Ehlers, Mario R, Nepom, Gerald T

“…Autoimmunity occurs when T cells, B cells or both are inappropriately activated, resulting in damage to one or more organ systems. Normally, high-affinity…”
Get full text

Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin by Xiao, Qian, Mears, Joseph, Nathan, Aparna, Ishigaki, Kazuyoshi, Baglaenko, Yuriy, Lim, Noha, Cooney, Laura A., Harris, Kristina M., Anderson, Mark S., Fox, David A., Smilek, Dawn E., Krueger, James G., Raychaudhuri, Soumya

“…Psoriasis is a chronic, systemic inflammatory condition primarily affecting skin. While the role of the immune compartment (e.g., T cells) is well established,…”
Get full text

Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial by Harris, Kristina M, Smilek, Dawn E, Byron, Margie, Lim, Noha, Barry, William T, McNamara, James, Garcet, Sandra, Konrad, Robert J, Stengelin, Martin, Bathala, Pradeepthi, Korman, Neil J, Feldman, Steven R, Boh, Erin E, Barber, Kirk, Laumann, Anne E, Helfrich, Yolanda Rosi, Krueger, Gerald G, Sofen, Howard, Bissonnette, Robert, Krueger, James G

“…Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept. To determine whether…”
Get more information

Editorial: Innovative approaches to immune tolerance and regulation with gene, cellular, protein, and microbiome based therapeutics by Rosenberg, Amy, Smilek, Dawn Elaine

Get full text

Approaches to Establishing Tolerance in Immune Mediated Diseases by Huffaker, Michelle F, Sanda, Srinath, Chandran, Sindhu, Chung, Sharon A, St Clair, E William, Nepom, Gerald T, Smilek, Dawn E

“…The development of rational approaches to restore immune tolerance requires an iterative approach that builds on past success and utilizes new mechanistic…”
Get full text

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis by Khoury, Samia J, Rochon, James, Ding, Linna, Byron, Margie, Ryker, Kristin, Tosta, Patti, Gao, Wendy, Freedman, Mark S, Arnold, Douglas L, Sayre, Peter H, Smilek, Dawn E

“…Background: Costimulatory blockade of T lymphocytes with the CTLA4-Ig fusion protein abatacept could be an effective treatment for the immune-mediated…”
Get full text

Solving the puzzle of autoimmunity: critical questions by Smilek, Dawn E, St Clair, E William

“…Despite recent advances in delineating the pathogenic mechanisms of autoimmune disease, the puzzle that reveals the true picture of these diverse immunological…”
Get full text

The immune cell landscape in kidneys of patients with lupus nephritis by Arazi, Arnon, Rao, Deepak A., Berthier, Celine C., Davidson, Anne, Liu, Yanyan, Hoover, Paul J., Chicoine, Adam, Eisenhaure, Thomas M., Jonsson, A. Helena, Li, Shuqiang, Lieb, David J., Zhang, Fan, Slowikowski, Kamil, Browne, Edward P., Noma, Akiko, Sutherby, Danielle, Steelman, Scott, Smilek, Dawn E., Tosta, Patti, Apruzzese, William, Massarotti, Elena, Dall’Era, Maria, Park, Meyeon, Kamen, Diane L., Furie, Richard A., Payan-Schober, Fernanda, Pendergraft, William F., McInnis, Elizabeth A., Buyon, Jill P., Petri, Michelle A., Putterman, Chaim, Kalunian, Kenneth C., Woodle, E. Steve, Lederer, James A., Hildeman, David A., Nusbaum, Chad, Raychaudhuri, Soumya, Kretzler, Matthias, Anolik, Jennifer H., Brenner, Michael B., Wofsy, David, Hacohen, Nir, Diamond, Betty

“…Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of…”
Get full text

Profiling CIS progression and stability using RNA-seq single-cell analysis in peripheral blood mononuclear cells by Giarraputo, James, Jain, Vaibhav, Arvai, Stephanie, Smilek, Dawn E, Harris, Kristina M, Gregory, Simon

“…Abstract Objective: To use single-cell mRNA analyses to identify immune cell profiles in CIS patients associated with a higher risk of developing an MS relapse…”
Get full text

Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study by Askanase, Anca, Byron, Margie, Keyes-Elstein, Lynette, Cagnoli, Patricia, McCune, W. Joseph, Chatham, W. Winn, Contreras, Gabriel, Daikh, David, Dall'Era, Maria, Wofsy, David, Davidson, Anne, Diamond, Betty, Mackay, Meggan, Ding, Linna, Gao, Wendy, Dooley, Mary Anne, Fragoso-Loyo, Hilda, Sanchez-Guerrero, Jorge, Karp, David, Olsen, Nancy, Jolly, Meenakshi, Kalunian, Kenneth, Kamen, Diane, Lee, Iris, Levesque, Marc C., Lim, S. Sam, Ramos-Remus, Cesar, Rovin, Brad, Sayre, Peter, Smilek, Dawn, Tosta, Patti, Utset, Tammy, Venuturupalli, Swamy, Winchester, Robert

“…Objective To assess the efficacy and safety of a 24‐week course of abatacept in the treatment of active lupus nephritis and to assess the potential of…”
Get full text

Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance by Glatigny, Simon, Höllbacher, Barbara, Motley, Samantha J, Tan, Cathy, Hundhausen, Christian, Buckner, Jane H, Smilek, Dawn, Khoury, Samia J, Ding, Linna, Qin, Tielin, Pardo, Jorge, Nepom, Gerald T, Turka, Laurence A, Harris, Kristina M, Campbell, Daniel J, Bettelli, Estelle

“…Abatacept is a CTLA-4-Ig fusion protein that binds to the costimulatory ligands CD80 and CD86 and blocks their interaction with the CD28 and CTLA-4 receptors…”
Get full text

Experimental Autoimmune Encephalomyelitis Induced with a Combination of Myelin Basic Protein and Myelin Oligodendrocyte Glycoprotein Is Ameliorated by Administration of a Single Myelin Basic Protein Peptide by Leadbetter, Elizabeth A, Bourque, Cheryl R, Devaux, Brigitte, Olson, Carl D, Sunshine, Geoffrey H, Hirani, Shirish, Wallner, Barbara P, Smilek, Dawn E, Happ, Mary Pat

“…Multiple sclerosis is an autoimmune disease of the central nervous system in which T cell reactivity to several myelin proteins, including myelin basic protein…”
Get full text

Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response by Fava, Andrea, Wagner, Catriona A., Guthridge, Carla J., Kheir, Joseph, Macwana, Susan, DeJager, Wade, Gross, Tim, Izmirly, Peter, Belmont, H. Michael, Diamond, Betty, Davidson, Anne, Utz, Paul J., Weisman, Michael H, Magder, Laurence S., Lee, Chun‐Hao, Fine, Derek, Monroy‐Trujillo, Manny, Anolik, Jennifer, Shah, Ummara, Ishimori, Mariko, Clancy, Robert M., Belmont, Michael, Wu, Ming, Bornkamp, Nicole, Putterman, Chaim, Der, Evan, Goilav, Beatrice, Jordan, Nicole, Schwartz, Daniel, Pullman, James, Wofsy, David, Smilek, Dawn, Tosta, Patti, Kretzler, Matthias, Berthier, Celine C., Woodle, E. Steve, Hildeman, Dave, Brenner, Michael, Rao, Deepak, Guthridge, Joel M., Petri, Michelle, Buyon, Jill, James, Judith A.

“…Objective Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response are not adequately known. In this…”
Get full text

Minimum Structural Requirements for Peptide Presentation by Major Histocompatibility Complex Class II Molecules: Implications in Induction of Autoimmunity by Gautam, Anand M., Lock, Christopher B., Smilek, Dawn E., Pearson, Cecelia I., Steinman, Lawrence, McDevitt, Hugh O.

“…The precise mechanisms of failure of immunological tolerance to self proteins are not known. Major histocompatibility complex (MHC) susceptibility alleles, the…”
Get full text

Abatacept targets Tfh and Treg, disrupting molecular pathways that regulate their proliferation and maintenance by Glatigny, Simon, Höllbacher, Barbara, Motley, Samantha J., Tan, Cathy, Hundhausen, Christian, Buckner, Jane H., Smilek, Dawn, Khoury, Samia J., Ding, Linna, Qin, Tielin, Pardo, Jorge, Nepom, Gerald T., Turka, Laurence A., Harris, Kristina M., Campbell, Daniel J., Bettelli, Estelle

“…Abatacept is a CTLA-4-Ig fusion protein that binds to the costimulatory ligands CD80 and CD86 and blocks their interaction with the CD28 and CTLA-4 receptors…”
Get full text

Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis by Arazi, Arnon, Rao, Deepak A., Berthier, Celine C., Davidson, Anne, Liu, Yanyan, Hoover, Paul J., Chicoine, Adam, Eisenhaure, Thomas M., Jonsson, A. Helena, Li, Shuqiang, Lieb, David J., Zhang, Fan, Slowikowski, Kamil, Browne, Edward P., Noma, Akiko, Sutherby, Danielle, Steelman, Scott, Smilek, Dawn E., Tosta, Patti, Apruzzese, William, Massarotti, Elena, Dall’Era, Maria, Park, Meyeon, Kamen, Diane L., Furie, Richard A., Payan-Schober, Fernanda, Pendergraft, William F., McInnis, Elizabeth A., Buyon, Jill P., Petri, Michelle A., Putterman, Chaim, Kalunian, Kenneth C., Woodle, E. Steve, Lederer, James A., Hildeman, David A., Nusbaum, Chad, Raychaudhuri, Soumya, Kretzler, Matthias, Anolik, Jennifer H., Brenner, Michael B., Wofsy, David, Hacohen, Nir, Diamond, Betty

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis by Smilek, Dawn Elaine, Lim, Noha, Ding, Linna, Murray, Sara G., Diamond, Betty, Wofsy, David

“…ObjectiveTo evaluate hypogammaglobulinaemia and risk of serious infectious adverse events in active lupus nephritis.MethodsThe Abatacept and Cyclophosphamide…”
Get full text